NL-OMON23732已完成不适用
The REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization
The Sint Maartenskliniek0 个研究点目标入组 140 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Rheumatoid arthritis: either 2010 ACR RA and/or 1987 RA criteria and/or clinical diagnosis of the treating rheumatologist, fulfilled at any time point between start of the disease and inclusion.
- •RTX retreatment: at least once RTX in the last 18 months for RA in a dose of 1 × 1000 mg, 2 × 1000 mg or 2 × 500 mg and no other biologicals received after last RTX dose. Patients treated with innovator RTX (MabThera) as well as registered biosimilars will be included.
排除标准
- •Patients with known (non-)response to ultra-low dose RTX (below 1 × 1000 mg)
- •Current corticosteroid dosing above 10 mg per day prednisolone equivalent
研究者
相似试验
进行中（未招募）
1 期
REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritisRheumatoid arthritisEUCTR2016-002908-15-NLSint Maartenskliniek140
Unknown
不适用
Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?RemissionRheumatoid ArthritisNCT02140229Assistance Publique - Hôpitaux de Paris450
终止
2 期
Lovastatin for the Treatment of Mildly Active Rheumatoid ArthritisRheumatoid ArthritisNCT00302952National Institute of Allergy and Infectious Diseases (NIAID)64
暂停
不适用
The RAINBOW study: Rheumatoid Arthritis ImplemeNtation of Biological dose Optimization in real WorldRheumatoid Arthritis (RA)NL-OMON22185This is an investigator-initiated study, funded by the Sint Maartenskliniek320
已完成
不适用
BeSt, BehandelStrategieën in Reumatoïde Artritis.NL-OMON24149Dutch College of Health Insurance Companies508